Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Royalty Pharma (NASDAQ:RPRX) has announced its participation in Bernstein's 2nd Annual Healthcare Forum. The company will engage in a fireside chat on Tuesday, September 23, 2025 at 2:50 p.m. ET. Investors can access the webcast through Royalty Pharma's "Events" page on their investor relations website, where it will remain archived for at least thirty days.
Royalty Pharma (NASDAQ:RPRX) ha annunciato la sua partecipazione al Bernstein's 2nd Annual Healthcare Forum. L'azienda parteciperà a una chiacchierata informale martedì, 23 settembre 2025 alle 14:50 ET. Gli investitori possono accedere al webcast tramite la pagina "Events" del sito di relazioni con gli investitori di Royalty Pharma, dove rimarrà archiviato per almeno trenta giorni.
Royalty Pharma (NASDAQ:RPRX) ha anunciado su participación en Bernstein's 2nd Annual Healthcare Forum. La empresa participará en una conversación informal el martes 23 de septiembre de 2025 a las 2:50 p.m. ET. Los inversores pueden acceder al webcast a través de la página "Events" del sitio de relaciones con inversores de Royalty Pharma, donde permanecerá archivado por al menos treinta días.
Royalty Pharma (NASDAQ:RPRX)이 Bernstein의 2nd Annual Healthcare Forum에 참여를 발표했습니다. 회사는 2025년 9월 23일 화요일 14:50 ET에 파이어사이드 채팅에 참여합니다. 투자자들은 로열티 파마의 IR 웹사이트의 "Events" 페이지를 통해 webcast에 접속할 수 있으며, 최소 30일 동안 보관됩니다.
Royalty Pharma (NASDAQ:RPRX) a annoncé sa participation au Bernstein's 2nd Annual Healthcare Forum. L'entreprise participera à une discussion informelle mardi 23 septembre 2025 à 14h50 HE. Les investisseurs peuvent accéder au webcast via la page "Events" du site des relations investisseurs de Royalty Pharma, où il restera archivé pendant au moins trente jours.
Royalty Pharma (NASDAQ:RPRX) hat seine Teilnahme am Bernstein's 2nd Annual Healthcare Forum angekündigt. Das Unternehmen wird an einem Fireside Chat am Dienstag, 23. September 2025 um 14:50 Uhr ET teilnehmen. Investoren können den Webcast über die Seite "Events" der Investor-Relations-Website von Royalty Pharma aufrufen, wo er mindestens dreißig Tage lang archiviert wird.
Royalty Pharma (NASDAQ:RPRX) أعلنت عن مشاركتها في Bernstein's 2nd Annual Healthcare Forum. ستشارك الشركة في محادثة بجلسة تشبه الجلسة حول الموقد الثلاثاء 23 سبتمبر 2025 الساعة 2:50 م بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين الوصول إلى البث عبر صفحة "Events" على موقع علاقات المستثمرين لـ Royalty Pharma، حيث سيظل متاحاً للأرشفة لمدة لا تقل عن ثلاثين يوماً.
Royalty Pharma (NASDAQ:RPRX) 已宣布参加 Bernstein's 2nd Annual Healthcare Forum。该公司将于 2025年9月23日（星期二）东部时间下午2:50 进行一场 炉边聊天。投资者可以通过 Royalty Pharma 投资者关系网站的 “Events” 页面访问网络直播，该页面至少会存档30天。
- None.
- None.
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When is Royalty Pharma (RPRX) presenting at Bernstein's Healthcare Forum 2025?
How can investors access Royalty Pharma's presentation at the Bernstein Healthcare Forum?
How long will Royalty Pharma's Bernstein Healthcare Forum presentation be available online?
What type of presentation will Royalty Pharma give at the Bernstein Healthcare Forum?
